EMA medicine approvals — GLP-1 and dual-agonist products

Placeholder seed entry recording the source, not an event. The European Medicines Agency publishes decisions on marketing authorisation. Approval status matters to this index because it determines whether the substance in a research-grade vial has an approved counterpart at all — and therefore whether a published trial literature exists for a product that is not the one being sold.